IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0776 -0,0008 (-0,08%) Petróleo Brent
82,92 -0,96 (-1,14%) Oro
2.369,40 +29,10 (+1,24%) Bitcoin EUR
56.277,30 -1.568,08 (-2,71%)
NovoCure Limited (NVCR)
NovoCure Limited
No. 4 The Forum
Second Floor Grenville Street
Saint Helier JE2 4UF
Jersey
44 15 3475 6700
https://www.novocure.com
Sector(es): Healthcare
Sector: Medical Devices
Empleados a tiempo completo: 1453
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. William F. Doyle | Executive Chairman | 1,43M | N/A | 1962 |
| Mr. Asaf Danziger | CEO & Director | 1,52M | 21,48M | 1966 |
| Ms. Ashley Cordova | Chief Financial Officer | 814,81k | 62,22k | 1979 |
| Mr. Wilhelmus C. M. Groenhuysen | Chief Operating Officer | 965,56k | N/A | 1958 |
| Mr. Michael Puri | Chief Human Resources Officer | N/A | N/A | 1969 |
| Mr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer | N/A | N/A | 1979 |
| Mr. Piet Hinoul M.D., Ph.D. | Senior VP, Head of Global Medical Affairs & Interim Head of Medical | N/A | N/A | N/A |
| Dr. Nicolas Leupin M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1973 |
Descripción
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Gobierno corporativo
El ISS Governance QualityScore de NovoCure Limited, a día 1 de mayo de 2024, es 2. Las puntuaciones base son Auditoría: 1; Tablero: 4; Derechos de los accionistas: 3; Compensación: 5.
